Nature Reviews Neurology

Papers
(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Lymphatic propagation of α-synuclein518
Microglia, spreaders of Aβ seeds313
Transmembrane protein interacts with α-synuclein to confer risk of PD303
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma291
Ventricular enlargement caused by aducanumab281
Brain stimulation aids walking after spinal injury246
Refining oxytocin therapy for autism: context is key242
Reply to ‘Perils and pitfalls of near-death experience research’216
Global synergistic actions to improve brain health for human development214
Neural cell state shifts and fate loss in ageing and age-related diseases214
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms212
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications208
NODDI reveals brain microstructural changes in multiple sclerosis202
Disease-specific modifications of tau protein186
Continuous levodopa production by an artificial enzyme185
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking179
Spinal muscular atrophy treatment in utero174
Nir Giladi (1955–2024)171
SEQUINS — a new initiative to address disparities in neurology149
The impact of rare genetic variants on Alzheimer disease142
Mitochondrial DNA instability in Huntington disease136
The Digitized Memory Clinic136
Study reveals new ALS risk genes135
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause128
TREM2 mediates phagocytosis in glioblastoma126
Microglia subset associated with high-grade glioma125
Imperatives and co-benefits of research into climate change and neurological disease120
The role of the gut microbiota in multiple sclerosis115
Ultrasound lets gene therapy into the brain108
Brain volume is associated with cognition in MS107
Role for endogenous retrovirus in FTD106
Amyloid plaques: hotspots for microglial turnover104
Menopause influences tau pathology104
Neurological care for LGBT+ people103
Implications of AD plasma and PET biomarker discordance102
Neuroinflammation predicts cognitive decline in FTD100
Psychosis-causing lesions mapped to a hippocampal circuit97
The challenges of anti-tau therapeutics in Alzheimer disease96
MRI-based deep learning for TLE diagnosis94
Diversity, equity and inclusion in neurology93
Brain imaging illuminates cognitive impairment in multiple sclerosis93
Author Correction: Viral pathogens increase risk of neurodegenerative disease86
Parkinson disease pathology can originate in the kidney85
First trials test targeting of α-synuclein for Parkinson disease85
Gene therapy for seizures in focal cortical dysplasia84
Precision neuroimmunology in multiple sclerosis — the horizon is near83
α-Synuclein pathology as a target in neurodegenerative diseases80
Management of freezing of gait — mechanism-based practical recommendations80
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice77
APOE ε4 influences Parkinson disease progression75
Blood GFAP as an emerging biomarker in brain and spinal cord disorders74
Challenges of combining multimodal data in assessment of people with traumatic brain injury72
Food is brain medicine — relevance and translation to neurology71
Evidence for altered astrocyte function in Duchenne muscular dystrophy71
Neurosteroids alleviate seizures in rats70
Glymphatic dysfunction in PD clinical progression68
Thalamic inflammation — a therapeutic target for brain injury?66
A new biological classification for Parkinson disease66
Exosomal microRNA is promising biomarker in PD64
Addressing disparities in neurology by building the workforce in LMICs61
Ultrasound ablation treatment for PD60
Coeliac disease as a model for understanding multiple sclerosis59
Spinal cord stimulation for the treatment of chronic pain59
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus58
New IDEAS about amyloid, race and dementia disparities56
Apparent changes in the epidemiology and severity of multiple sclerosis55
The global and regional burden of diabetic peripheral neuropathy54
Post-COVID dysautonomias: what we know and (mainly) what we don’t know53
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease52
Is Alzheimer disease a disease?52
The role of glial cells in multiple sclerosis disease progression50
Synaptic degeneration in Alzheimer disease50
From the prodromal stage of multiple sclerosis to disease prevention50
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus48
Hypothalamus loses control in migraine47
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions47
Oligomeric tau could spread through synapses in AD45
Hypothyroidism is associated with dementia risk44
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis44
X-chromosome variants and PD in Latin America44
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence44
Peripheral nervous system immune-related adverse events due to checkpoint inhibition43
Neurofilament light chain induces neuroinflammation43
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases42
Cognitive impairment and World Trade Centre-related exposures41
Global epidemiology of migraine and its implications for public health and health policy41
The inter-relationship between delirium and dementia: the importance of delirium prevention40
Safety and efficacy of COVID-19 vaccines in people with neurological disorders38
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction38
Moving towards meaningful patient and public engagement38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis38
Dual function of biomolecular condensates38
Risk locus for paediatric astrocytoma identified37
Change in stroke outcomes over 20 years36
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders36
α-Synuclein seeds in amyotrophic lateral sclerosis36
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease36
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci35
Prognostic plasma biomarkers for spinal cord injury35
CAR T cells offer hope in glioblastoma34
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management33
Huntington disease-like 2: insight into neurodegeneration from an African disease33
New developments in guidelines for brain death/death by neurological criteria32
Facioscapulohumeral muscular dystrophy: the road to targeted therapies31
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology31
Positron emission tomography in multiple sclerosis — straight to the target31
Origins and immunopathogenesis of autoimmune central nervous system disorders31
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology29
Inflammasomes in neurological disorders — mechanisms and therapeutic potential25
Twin study probes non-heritable immune aspects of multiple sclerosis24
Charting brain development across the human lifespan24
Neurogenesis altered in multiple neurodegenerative diseases24
Serum NfL as an MS biomarker24
Deep learning distinguishes tauopathies24
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease24
High rate of epilepsy in young individuals who died with COVID-1924
Does antiherpetic antiviral therapy reduce the risk of dementia?23
AI and protein structure and function in neurological disease: relevance to disease management21
John Q. Trojanowski21
ALS pathogenesis linked to actin barrier collapse20
Aberrant protein networks in Alzheimer disease20
BCAS1+ oligodendrocytes aid remyelination in MS19
Author Correction: The complex aetiology of cerebral palsy19
Pharmacological rehabilitation for stroke19
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era19
AI aces diagnosis of chronic ataxias18
Pathogenetic mechanisms and treatment targets in cerebral malaria17
Neuroprognostication: a conceptual framework17
The murky waters of sex differences in post-stroke cognitive impairment17
Addressing disparities in the global epidemiology of stroke16
Alzheimer disease in African American individuals: increased incidence or not enough data?16
Genome-wide analysis furthers decoding of Alzheimer disease genetics14
Molecular biomarkers for vascular cognitive impairment and dementia14
Effects of diet on MS onset and course13
Clocking the age of Parkinson disease onset13
Nusinersen treatment response markers13
Altered muscle cholesterol transport in ALS12
Predictive tools in psychosis: what is ‘good enough’?12
Nanoprobe for blood–brain barrier changes12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis12
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms12
Multidimensional MRI detects astrogliosis11
Mechanistic insights into the interaction between epilepsy and sleep11
Seizure-associated changes in the Golgi apparatus11
Advancing multiple sclerosis management in older adults11
Markers help to predict dementia with Lewy bodies11
Sex and gender in neurodevelopmental conditions11
Alzheimer disease seen through the lens of sex and gender11
0.13528800010681